Kairos Pharma (NYSE: KAPA) to share initial ENV105 Phase 1 lung cancer data

Rhea-AI Filing Summary

Kairos Pharma, Ltd. filed a report describing a recent corporate update. On September 3, 2025, the company issued a press release announcing its participation in the World Lung Cancer Conference in Barcelona, Spain. At this meeting, Principal Investigator Dr. Karen Reckamp is scheduled to present initial Phase 1 data for the company’s drug candidate ENV105 in non-small cell lung cancer.

The conference is taking place from September 6–9, 2025 at the Fira de Barcelona Gran Via. The press release with additional details is provided as Exhibit 99.1 to the report and is being furnished rather than filed, meaning it is not incorporated into the company’s other Securities Act or Exchange Act filings by default.

false 0001962011 0001962011 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

Kairos Pharma, Ltd.

(Exact name of registrant as specified in its charter)

Delaware		001-42275		46-2993314
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2355 Westwood Blvd., #139

Los Angeles CA 90064

(Address of principal executive offices) (Zip Code)

(310) 948-2356

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol (s)		Name of each exchange on which registered
Common Stock, par value $0.001, per share		KAPA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 3, 2025, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), issued a press release announcing its participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025 at the Fira de Barcelona Gran Via in Barcelona, Spain.

A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Item 8.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01, including Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated September 3, 2025
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 3, 2025	KAIROS PHARMA, LTD.
	By:	/s/ John S. Yu
		John S. Yu
		Chief Executive Officer

FAQ

What did Kairos Pharma (KAPA) disclose in this 8-K filing?

Kairos Pharma disclosed that it issued a press release announcing its participation in the World Lung Cancer Conference and the presentation of initial Phase 1 ENV105 data in non-small cell lung cancer.

What is being presented by Kairos Pharma at the World Lung Cancer Conference?

Principal Investigator Dr. Karen Reckamp will present initial Phase 1 clinical data for Kairos Pharma’s candidate ENV105 in non-small cell lung cancer.

When and where is the World Lung Cancer Conference mentioned by Kairos Pharma (KAPA)?

The World Lung Cancer Conference is scheduled for September 6–9, 2025 at the Fira de Barcelona Gran Via in Barcelona, Spain.

How did Kairos Pharma (KAPA) make the ENV105 update available to investors?

The company issued a press release dated September 3, 2025, which is included as Exhibit 99.1 to the report and furnished under Item 8.01.

Is the Kairos Pharma ENV105 press release considered filed with the SEC?

No. The company states that the information in Item 8.01 and Exhibit 99.1 is furnished, not filed, and is not automatically incorporated by reference into its other Securities Act or Exchange Act filings.

Who signed the Kairos Pharma (KAPA) 8-K related to the ENV105 presentation?

The report was signed on behalf of Kairos Pharma, Ltd. by John S. Yu, who is identified as the company’s Chief Executive Officer.